266 related articles for article (PubMed ID: 34118956)
1. Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison.
Ogita M; Yamashita H; Nozawa Y; Ozaki S; Sawayanagi S; Ohta T; Nakagawa K
Radiat Oncol; 2021 Jun; 16(1):107. PubMed ID: 34118956
[TBL] [Abstract][Full Text] [Related]
2. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.
Hwang ME; Black PJ; Elliston CD; Wolthuis BA; Smith DR; Wu CC; Wenske S; Deutsch I
Radiat Oncol; 2018 Oct; 13(1):192. PubMed ID: 30285812
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
5. SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review.
Payne HA; Pinkawa M; Peedell C; Bhattacharyya SK; Woodward E; Miller LE
Medicine (Baltimore); 2021 Dec; 100(49):e28111. PubMed ID: 34889268
[TBL] [Abstract][Full Text] [Related]
6. Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
Lewin R; Amit U; Laufer M; Berger R; Dotan Z; Domachevsky L; Davidson T; Portnoy O; Tsvang L; Ben-Ayun M; Weiss I; Symon Z
Radiat Oncol; 2021 Jun; 16(1):114. PubMed ID: 34162398
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
[TBL] [Abstract][Full Text] [Related]
8. Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy.
Saito M; Suzuki T; Sugama Y; Marino K; Sano N; Komiyama T; Aoki S; Maehata Y; Yoshizawa K; Ashizawa K; Suzuki H; Ueda K; Miyasaka Y; Araya M; Takahashi H; Onishi H
J Radiat Res; 2020 May; 61(3):487-493. PubMed ID: 32211861
[TBL] [Abstract][Full Text] [Related]
9. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
Ruggieri R; Naccarato S; Stavrev P; Stavreva N; Fersino S; Giaj Levra N; Mazzola R; Mancosu P; Scorsetti M; Alongi F
Br J Radiol; 2015 Oct; 88(1054):20140736. PubMed ID: 26235142
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial.
See AW; Bowden P; Wells G; Appu S; Lawrentschuk N; Liodakis P; Pandeli C; Aarons Y; Smyth LML; McKenzie DP
Radiat Oncol; 2022 Jul; 17(1):131. PubMed ID: 35879722
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function.
Hwang ME; Mayeda M; Shaish H; Elliston CD; Spina CS; Wenske S; Deutsch I
Br J Radiol; 2021 Mar; 94(1119):20200433. PubMed ID: 33586999
[TBL] [Abstract][Full Text] [Related]
12. Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy.
Chao M; Ho H; Chan Y; Tan A; Pham T; Bolton D; Troy A; Temelcos C; Sengupta S; McMillan K; Cham CW; Liu M; Ding W; Subramanian B; Wasiak J; Lim Joon D; Spencer S; Lawrentschuk N
BJU Int; 2018 Sep; 122(3):427-433. PubMed ID: 29520983
[TBL] [Abstract][Full Text] [Related]
13. Distribution analysis of hydrogel spacer and evaluation of rectal dose reduction in Japanese prostate cancer patients undergoing stereotactic body radiation therapy.
Kobayashi H; Eriguchi T; Tanaka T; Ogata T; Ishida M; Nakajima Y; Kumabe A; Kosugi M
Int J Clin Oncol; 2021 Apr; 26(4):736-743. PubMed ID: 33415570
[TBL] [Abstract][Full Text] [Related]
14. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Br J Radiol; 2021 Jan; 94(1117):20200848. PubMed ID: 33095659
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
16. Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer.
Sawayanagi S; Yamashita H; Ogita M; Takenaka R; Nozawa Y; Watanabe Y; Imae T; Abe O
Radiat Oncol; 2022 Feb; 17(1):41. PubMed ID: 35197092
[TBL] [Abstract][Full Text] [Related]
17. A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer.
Kainuma T; Kawakami S; Tsumura H; Satoh T; Tabata KI; Iwamura M; Hayakawa K; Ishiyama H
Radiat Oncol; 2019 Sep; 14(1):158. PubMed ID: 31477122
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
19. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.
Mariados N; Sylvester J; Shah D; Karsh L; Hudes R; Beyer D; Kurtzman S; Bogart J; Hsi RA; Kos M; Ellis R; Logsdon M; Zimberg S; Forsythe K; Zhang H; Soffen E; Francke P; Mantz C; Rossi P; DeWeese T; Hamstra DA; Bosch W; Gay H; Michalski J
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):971-977. PubMed ID: 26054865
[TBL] [Abstract][Full Text] [Related]
20. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F
Radiat Oncol; 2020 Jul; 15(1):178. PubMed ID: 32698843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
